Condition
Familial Amyloid Polyneuropathy
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
5 of 5 completed with results
Key Signals
5 with results100% success
Data Visualizations
Phase Distribution
5Total
P 2 (4)
P 3 (1)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02175004Phase 3Completed
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
NCT01737398Phase 2Completed
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
NCT00294671Phase 2CompletedPrimary
The Effect of Diflunisal on Familial Amyloidosis
NCT00409175Phase 2CompletedPrimary
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
NCT00791492Phase 2CompletedPrimary
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
Showing all 5 trials